Patent · US Active

Antisense-oligonucleotides as inhibitors of TGF-R signaling

US11213541B2 · kind B2 · utility

1Cited by

0References

5Claims

0Family size

Assignee

NEUROVISION PHARMA GMBH · DE

Inventors

Markus Hossbach · Kulmbach, DE
Monika Krampert · Bamberg, DE
Hans-Lothar Arth · Berlin, DE

Key dates

Filing date	Nov 16, 2015
Grant date	Jan 4, 2022
Priority date	—
Expiry date	Dec 25, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/1103
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.